Research teams unite for research on Lou Gehrig's Disease

December 10, 2013 by Chelsea Whyte

Lisa Miller and Paul Gelfand, biophysical chemists at the U.S. Department of Energy's Brookhaven National Laboratory, recently visited the Advanced Photon Source at Argonne National Laboratory to supplement their research into the cause of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

They're studying the genetic form of the disease, which is caused by a mutation in a gene that instructs cells to make a particular protein within the . When the gene is mutated, the protein folds abnormally, clumping into aggregates that cause paralysis and eventually death.

"This protein uses two metals to fold correctly – copper and zinc," says Gelfand. "We can use the x-ray beams at a synchrotron to look at the status of the copper and zinc relative to the motor neurons in the spinal cord."

Getting a clear picture of structural deformations in extremely small biological samples requires tiny x-ray beams—smaller than what's currently available at Brookhaven's National Synchrotron Light Source (NSLS).

"We're using the very tiny beams at the Advanced Photon Source in order to focus in on those tiny aggregates, to understand how much copper there is, how much zinc there is, if there's any, to help us understand why the aggregates form and why paralysis happens," says Miller.

"If we understand why the protein is misfolding, it's possible to create drugs or develop techniques to rescue the protein before it misfolds," Gelfand says.

The video will load shortly

The scientists' work will continue at the National Synchrotron Light Source II at Brookhaven, using the nanoscale-size beams at the Submicron Resolution X-Ray Spectroscopy Beamline when it begins operation in 2015.

Explore further: Elevated levels of copper in amyloid plaques associated with neurodegeneration in mouse models of AD

Related Stories

Brain iron as an early predictor of Alzheimer's disease

June 17, 2011

Early and correct diagnosis of Alzheimer’s disease (AD) is important for reasons that go beyond treatment. These include more time to make critical life decisions, planning for future care, and maximizing the safety ...

Recommended for you

New, more effective strategy for producing flu vaccines

December 5, 2016

A team of researchers led by Yoshihiro Kawaoka, professor of pathobiological sciences at the University of Wisconsin-Madison School of Veterinary Medicine, has developed technology that could improve the production of vaccines ...

Another step closer to artificial blood

December 5, 2016

(HealthDay)—Artificial blood stored as a powder could one day revolutionize emergency medicine and provide trauma victims a better chance of survival.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.